Syndax Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Syndax Pharmaceuticals, Inc. (SNDX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $81.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $81.10M, a 53.89% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $52.70M, a 27.71% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $72.90M, a 103.06% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $35.90M, a 647.92% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $81.10M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $52.70M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $72.90M 10-K · filed 2025-03-03 | |
| 2022-12-31 | $35.90M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $4.80M 10-K · filed 2023-02-28 | -$4.80M 10-K · filed 2022-03-01 |
| 2020-12-31 | $17.50M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $12.80M 10-K · filed 2021-03-12 | |
| 2018-12-31 | $17.20M 10-K · filed 2020-03-05 | |
| 2017-12-31 | -$5.90M 10-K · filed 2019-03-07 | |
| 2016-12-31 | $13.00M 10-K · filed 2018-03-08 | |
| 2015-12-31 | $6.60M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |